The author discusses the need to have live tumour databanks and genomic neuroendocrine neoplasms (NENs) mapping in Canada. He says that the lack of tumour databanks is unfavourable to the country with the statistics showing high NEN records and the late diagnosis for the disease in the country. He adds that Canadian NENs patients lack the access for clinical trials and new drugs that are accessible in other countries.